Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

2,550

Participants

Timeline

Start Date

February 18, 2023

Primary Completion Date

January 5, 2024

Study Completion Date

January 5, 2024

Conditions
Prevention of Influenza
Interventions
BIOLOGICAL

Investigational Vaccine(0.25ml/vial)

Subjects were vaccinated with a dose of low-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.

BIOLOGICAL

Investigational Vaccine(0.5ml/vial)

Subjects were vaccinated with a dose of high-dose Investigational vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.

BIOLOGICAL

Active compared Vaccine

Subjects were vaccinated with a dose of active compared vaccine on day 0 and day 28 respectively.The site of inoculation for infants aged 6-11 months is the anterolateral thigh, and the site of inoculation for infants aged 12-35 months is the lateral deltoid muscle of the upper arm.

Trial Locations (1)

410005

Hunan Provincial Center for Disease Control and Prevention, Changsha

All Listed Sponsors
lead

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

INDUSTRY